Publications (13)29.01 Total impact
-
Article: Disparate results in studies of adalimumab in the treatment of hidradenitis suppurativa: comment on the article by Amano et al.
International journal of dermatology 03/2013; 52(3):380-381. · 1.18 Impact Factor -
Article: Interstitial keratitis secondary to severe hidradenitis suppurativa responding to adalimumab.
Cornea 12/2011; 31(2):206; author reply 206. · 1.73 Impact Factor -
Article: Cutaneous plasmacytosis limited to the extremities in a white patient: an unusual clinical picture.
[show abstract] [hide abstract]
ABSTRACT: Cutaneous plasmacytosis is an uncommon disease characterized by a cutaneous polyclonal plasma cell infiltrate usually associated with polyclonal hypergammaglobulinemia. It has predominantly been found in Japanese patients and it is rare in white patients. Clinically, this condition manifests as multiple red to dark brown skin lesions that mainly are located on the trunk. We report the case of a 66-year-old white woman who presented with reddish brown to violaceous macules and plaques restricted to the extremities. The histopathologic findings, laboratory data, and systemic studies led us to the diagnosis of cutaneous plasmacytosis.Cutis; cutaneous medicine for the practitioner 09/2010; 86(3):143-7. · 0.81 Impact Factor -
Article: Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
[show abstract] [hide abstract]
ABSTRACT: BACKGROUND: Several studies report the use of tumor necrosis factor alpha (TNF-alpha) inhibitors in refractory hidradenitis suppurativa (HS), particularly infliximab and etanercept. However, very limited data have been reported for adalimumab, the newest fully human anti-TNF-alpha monoclonal antibody. We evaluated the long-term efficacy and safety of adalimumab therapy in 6 patients with refractory HS. In the case of positive culture findings from any draining lesion, antibiotic therapy was administered for at least 2 weeks before initiating adalimumab therapy. Adalimumab (in 40-mg subcutaneous injections) was prescribed every other week. If the disease was inadequately controlled, the dosage was increased to 40 mg/wk. If HS was in persistent clinical remission, adalimumab therapy was gradually decreased to 40 mg every 3 weeks. Quality of life was assessed using the Dermatology Life Quality Index. OBSERVATIONS: Six patients (mean [SD] age, 39.3 [12.9] years) with severe HS (mean [SD] duration, 22.5 [11.7] years) were treated with adalimumab. Significant improvements after 1 month of treatment were seen in the Dermatology Life Quality Index; in the number of affected regions, nodules, and fistulas; and in the basic laboratory findings. Improvements were maintained for a mean (SD) follow-up of 21.5 (7.1) (range, 13-29) months. Adalimumab was well tolerated. Conclusion Adalimumab appears to be an effective and safe treatment for refractory HS.Archives of dermatology 06/2009; 145(5):580-4. · 4.76 Impact Factor -
Article: Cutaneous diffuse large B-cell lymphoma of the leg associated with chronic lymphedema.
[show abstract] [hide abstract]
ABSTRACT: Development of malignant tumors is a rare but well known complication in chronic lymphedema (CL). We report herein a cutaneous diffuse large B-cell lymphoma of the leg associated with CL. An 89-year-old man presented with multiple cutaneous lesions on his right limb that showed a CL. Dermatological examination disclosed multiple violaceous, firm, slightly infiltrated nodules on the anterior aspect of the leg and the dorsum and sole of the foot. A biopsy of one nodule of the leg disclosed a diffuse large B-cell lymphoma, type of the legs. There was no evidence of lymphadenopathy on computed tomography (CT) scans of the chest, abdomen, and pelvis. A bone marrow aspiration and biopsy showed normal results. The patient was treated with local radiotherapy at a dose of 40 Gy, obtaining a highly significant, almost complete, clinical remission. A literature search identified 11 additional cases of primary cutaneous lymphoma associated with CL. An inadequate lymphatic drainage may make the lymphedematous region an immunologically vulnerable area, predisposing to neoplasia.International journal of dermatology 03/2008; 47(2):174-7. · 1.18 Impact Factor -
Article: Collision of pigmented benign tumours: a possible simulator of melanoma.
Acta Dermato Venereologica 02/2008; 88(1):92-3. · 3.18 Impact Factor -
Article: Erythema annulare centrifugum in a HIV-positive patient.
International Journal of Dermatology 01/2007; 45(12):1423-5. · 1.14 Impact Factor -
Article: Development of sarcoidosis during etanercept therapy.
Arthritis & Rheumatism 11/2006; 55(5):817-20. · 7.87 Impact Factor -
Article: [Psoriasis induced by infliximab: a paradoxical event].
Medicina Clínica 10/2006; 127(8):316. · 1.38 Impact Factor -
Article: [Netherton syndrome].
[show abstract] [hide abstract]
ABSTRACT: Netherton syndrome is a rare disease inherited as an autosomal recessive trait due to mutations in the SPINK5 gene. It is characterized by the triad of ichthyosiform dermatosis, alterations of the hair shaft and immunological disorders. We present the case of a 12-year-old girl with the triad of ichthyosis linearis circumflexa, trichorrhexis invaginata and atopic dermatitis, characteristic of Netherton syndrome.Actas Dermo-Sifiliográficas 07/2006; 97(5):348-50. -
Article: Posttransplant Kaposi's sarcoma restricted to the site of a previous deep venous thrombosis: abrupt onset after withdrawal of sirolimus.
[show abstract] [hide abstract]
ABSTRACT: Kaposi's sarcoma (KS) is an angioproliferative neoplasia associated with human herpesvirus 8 (HHV-8) infection. HHV-8 generates KS by means of the secretion of vascular endothelial growth factor (VEGF) andup-regulation of VEGF receptor, KDR, in endothelial cells. We report a case of KS in a 72-year-old male with a renal transplant who had received immunosuppressant drugs including sirolimus, mycophenolate mofetil, tacrolimus and steroids. KS developed 11 months after transplantation, in relation to deep venous thrombosis and withdrawal of sirolimus due to toxicity. Multiple purple papules and nodules were observed exclusively in the limb affected by thrombosis. Diagnosis of KS was confirmed by biopsy. Progressive withdrawal of prednisone was accompanied by full remission of the tumour. The thrombosis and withdrawal of sirolimus may have acted as cofactors in the development of KS, favouring the activation of the VEGF/KDR autocrine loop. Our experience contributes to further evidence that sirolimus may protect against KS.Dermatology 02/2006; 213(1):30-3. · 2.05 Impact Factor -
Article: Fibroepithelioma of pinkus with tumor giant cells.
[show abstract] [hide abstract]
ABSTRACT: A case of fibroepithelioma of Pinkus with pleomorphic epithelial giant cells is reported. The lesion was an ovoid polypoid nodule measuring 4 mm x 3 mm x 2 mm and was located close to the right axilla in an 86-year-old woman. The immunohistochemical features of the epithelial giant cells indicate that most of these cells are not cycling. We suggest that these cellular changes may represent a senescent event. Giant cells showed a mean nuclear major diameter more than twice that of small cells. Flow cytometric study of the tumor showed a hypodiploid DNA content and an intermediate grade S-phase fraction of the aneuploid component. To the best of our knowledge, a pleomorphic variant of Pinkus fibroepithelioma has not been reported to date. In fibroepithelioma of Pinkus, the correct diagnosis depends primarily on the architectural pattern of the tumor rather than on its cytologic features.American Journal of Dermatopathology 09/2002; 24(4):336-9. · 1.20 Impact Factor -
Article: Cutaneous diffuse large B-cell lymphoma of the leg mimicking a chronic venous ulcer.
European journal of dermatology: EJD 17(1):92-3. · 2.53 Impact Factor
Top co-authors
Top Journals
Institutions
-
2007–2008
-
Universidad de Cantabria
- Facultad de Medicina
Santander, Cantabria, Spain
-
